Chronic mucopurulent rhinosinusitis is a common accompaniment of chronic or recurrent bronchial sepsis-for example, in patients with bronchiectasis and cystic fibrosis. It may be treated with systemic or topical medication, or both, but the response is often unsatisfactory. The 632 results were defined as eradication of a pathogenic organism isolated before treatment. The resolution of intranasal mucosal inflammation or hypertrophy was assessed by an ear, nose, and throat surgeon.
Results
The two groups of patients were of similar mean age (HB 49, HDF 54 years), and had similar symptoms and results before treatment (table) . Analysis ofdiary cards showed that patients using the HDF position responded significantly better to treatment than those using the HB position (X2 test, p < 0 025, 2 degrees of freedom). In the HDF position seven patients responded, one partially responded, and two did not respond. In the HB position one patient responded, two partially responded and seven did not respond. The results in terms of individual symptoms, and also results of investigations, are shown in the table; in each case patients using the HDF position responded more favourably.
Discussion
There is a large inflammatory component to mucopurulent sinusitis, which may contribute to chronic symptoms by reducing drainage and mucociliary clearance. The maxillary sinus is most frequently affected. Its ostium is situated high above the floor of the antrum, so that in the standing or sitting position clearance depends solely on mucociliary transport, which may be compromised during infection, leading to accumulation of bacteria and inflammatory secretions. 4 We therefore used a preparation combining a broad spectrum antibiotic with an anti-inflammatory agent.
Wilson, Sykes, Chan, Cole, Mackay Because the efficacy of this topical preparation may be reduced by poor distribution within the nose and paranasal sinuses,5 we addressed the question of the most favourable position for administration of the drops and showed that by adopting the HDF position a good response to topical medication can be achieved in patients with chronic mucopurulent rhinosinusitis. The poor response of the HB group may reflect the overall severity of disease in the patients studied, making it mandatory to maximise efficiency of drug delivery to the nasal and paranasal sinus mucosa to achieve the desired response.
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